The domestic pharmaceutical and bio-industry are changing clinical trial protocols and confirming the possibility of their use in combination therapy with antibody-drug conjugates (ADCs). In particular, a growing number of companies are trying to use their drugs in combination with Enterhu, which has shown an effect across solid cancers

For example, GI Innovation and AbClon are aiming to maximize the effectiveness of their existing immuno-oncology and targeted anti-cancer drugs by using their drug in combination with Enhertu. In particular, they expect to show benefits in terms of side effects by combining a reduced dose of Enhertu with their respective new drug candidates that are under development.